BC Week In Review | Jan 5, 2015
Company News

Daiichi Sankyo sales and marketing update

Daiichi’s Daiichi Sankyo Espha Co. Ltd. subsidiary launched generic versions of levofloxacin, candesartan cilexetil and IV oxaliplatin in Japan. Daiichi markets levofloxacin, a synthetic broad-spectrum oral fluoroquinolone antibiotic targeting bacterial DNA gyrase and topoisomerase , as...
BC Week In Review | Nov 17, 2014
Company News

Takeda cardiovascular news

Takeda announced new measures and disciplinary action as a result of inappropriate promotional activities utilizing results of the investigator-initiated Phase III CASE-J trial of Takeda's hypertension drug Blopress candesartan cilexetil. To prevent recurrences of such...
BC Week In Review | Jul 14, 2014
Company News

Takeda Pharmaceutical Co. Ltd cardiovascular news

Takeda said law firm Jones Day, a third-party investigator, did not find evidence that the pharma falsified or fabricated data or had direct involvement in statistical analysis work related to the investigator-initiated Phase III CASE-J...
BC Week In Review | Apr 14, 2014
Company News

Takeda cardiovascular news

Takeda said the Japan Pharmaceutical Manufacturers Association (JPMA) imposed sanctions on the company for promotional activities regarding the investigator-initiated Phase III CASE-J trial of the pharma's Blopress candesartan cilexetil for hypertension. Takeda was suspended for...
BC Week In Review | Mar 17, 2014
Company News

Takeda cardiovascular news

Takeda appointed law firm Jones Day as a third-party investigator in response to issues raised by the media regarding the investigator initiated Phase III CASE-J trial of the pharma's hypertension drug Blopress candesartan cilexetil. The...
BioCentury | Nov 5, 2012

Racing to rebuild AZ

AstraZeneca plc 's new CEO Pascal Soriot has not yet detailed his vision for the company, but comments last month on his first call with investors coupled with an early move to halt the company's...
BC Extra | Jun 8, 2012
Politics & Policy

EU Ombudsman critical of EMA decision in pediatric waiver case

The EU Ombudsman concluded EMA failed to provide adequate transparency and reasoning in its decision to waive pediatric trial requirements for only two of three angiotensin II receptor (type AT1) antagonists. The Ombudsman recommended drafting...
BC Week In Review | Oct 24, 2011
Clinical News

European Medicines Agency regulatory update

EMA's CHMP concluded that the benefit-risk balance of angiotensin receptor blockers (ARBs) is positive, and that evidence does not support an increased risk of cancer in patients on these drugs. CHMP conducted the review at...
BC Week In Review | Jun 6, 2011
Clinical News

Atacand candesartan cilexetil regulatory update

FDA completed a safety review of angiotensin receptor blockers (ARBs) and found no increased risk of cancer associated with the drugs. The agency said a meta-analysis of 31 trials with about 156,000 patients showed the...
BioCentury | May 23, 2011

Takeda's global boost

Acquiring Nycomed will transform Takeda Pharmaceutical Co. Ltd. into a complete global pharma company by combining geographically complementary marketing operations. But the Japanese pharma will need more acquisitions to get its market cap back to...
Items per page:
1 - 10 of 44